Format

Send to

Choose Destination
Blood. 2014 Aug 7;124(6):913-23. doi: 10.1182/blood-2013-12-546218. Epub 2014 Jun 9.

Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells.

Author information

1
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA;
2
Seattle Children's Research Institute, Seattle, WA;
3
Fred Hutchinson Cancer Research Center, Seattle, WA; and.
4
Seattle Children's Research Institute, Seattle, WA; Department of Pediatrics and Immunology, University of Washington School of Medicine, Seattle, WA.

Abstract

Transplantation of genetically modified hematopoietic stem cells (HSCs) is a promising therapeutic strategy for genetic diseases, HIV, and cancer. However, a barrier for clinical HSC gene therapy is the limited efficiency of gene delivery via lentiviral vectors (LVs) into HSCs. We show here that rapamycin, an allosteric inhibitor of the mammalian target of rapamycin complexes, facilitates highly efficient lentiviral transduction of mouse and human HSCs and dramatically enhances marking frequency in long-term engrafting cells in mice. Mechanistically, rapamycin enhanced postbinding endocytic events, leading to increased levels of LV cytoplasmic entry, reverse transcription, and genomic integration. Despite increasing LV copy number, rapamycin did not significantly alter LV integration site profile or chromosomal distribution in mouse HSCs. Rapamycin also enhanced in situ transduction of mouse HSCs via direct intraosseous infusion. Collectively, rapamycin strongly augments LV transduction of HSCs in vitro and in vivo and may prove useful for therapeutic gene delivery.

PMID:
24914132
PMCID:
PMC4126331
DOI:
10.1182/blood-2013-12-546218
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center